{"id":51831,"date":"2021-11-25T18:37:23","date_gmt":"2021-11-25T13:07:23","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=51831"},"modified":"2021-11-25T21:55:49","modified_gmt":"2021-11-25T16:25:49","slug":"einstein-jr-clinical-trials-of-rivaroxaban-in-children","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/","title":{"rendered":"EINSTEIN-Jr clinical trials of Rivaroxaban in children"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/Gq3JswrL3yM\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<h2><span style=\"color: #008000;\">EINSTEIN-Jr clinical trials of Rivaroxaban in children<\/span><\/h2>\n<p>Rivaroxaban is useful for treatment of venous thromboembolism in adults and is associated with lower risk of bleeding compared to standard anticoagulants. EINSTEIN-Jr phase 2 used bodyweight adjusted rivaroxaban for children with venous thromboembolism [1]. It was a single arm multicenter study three age groups &#8211; children younger than 6 months, those in age group 6 months to 5 years and in children and adolescents between 6-17 years. Studies were done at 54 sites across Australia, Europe, Israel, Japan and North America. The study was in children with confirmed venous thromboembolism who have been treated for at least 2 months low molecular weight heparin, fondaparinux or vitamin K antagonist. In children with catheter related venous thromboembolism the cut off for previous treatment was 6 weeks. 89 children (96%) completed study treatment. None of the children had major bleed. 4% had clinically relevant non-major bleed. There was no symptomatic recurrent venous thromboembolism. In 75 patients repeat imaging showed resolution of thrombus burden. 43 had improved and 8 were unchanged. No patient deteriorated in this study.<\/p>\n<p>EINSTEIN-Jr phase 3 was a multicenter, open label randomized study in children and adolescents up to the age of 17 years [2]. The study was conducted across 107 pediatric hospitals in 28 countries. Children with acute venous thromboembolism on heparin were assigned to either body weight adjusted rivaroxaban or standard anticoagulants. Symptomatic recurrent venous thromboembolism occurred in 1% of the 335 children in rivaroxaban group and 3% of the 165 receiving standard anticoagulants. Improved effect of rivaroxaban was noted on repeat imaging compared with standard anticoagulants. 3% of the children had non-major clinically relevant bleeding on rivaroxaban. Two major and one non-major bleeding episodes occurred in those on standard anticoagulants (2%). There were no treatment related deaths. Treatment with rivaroxaban resulted in low recurrence and reduced thrombotic burden, without an increase in bleeding, compared to standard anticoagulants. Thus the safety and efficacy of rivaroxaban in children was similar to that in adults [3].<\/p>\n<p><span style=\"color: #0000ff;\"><strong>References<\/strong><\/span><\/p>\n<ol>\n<li>Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamar\u00eda A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-G\u00f6ttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D; EINSTEIN-Jr Phase 2 Investigators. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31420317\/\">Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies<\/a>. Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016\/S2352-3026(19)30161-9. Epub 2019 Aug 13. PMID: 31420317.<\/li>\n<li>Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamar\u00eda A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, K\u00e1llay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P; EINSTEIN-Jr Phase 3 Investigators. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31699660\/\">Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial<\/a>. Lancet Haematol. 2020 Jan;7(1):e18-e27. doi: 10.1016\/S2352-3026(19)30219-4. Epub 2019 Nov 5. PMID: 31699660.<\/li>\n<li>O&#8217;Brien SH. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31699659\/\">Can paediatricians move directly to direct oral anticoagulants?<\/a> Lancet Haematol. 2020 Jan;7(1):e2-e3. doi: 10.1016\/S2352-3026(19)30204-2. Epub 2019 Nov 5. PMID: 31699659.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>EINSTEIN-Jr clinical trials of Rivaroxaban in children Rivaroxaban is useful for treatment of venous thromboembolism in adults and is associated with lower risk of bleeding compared to standard anticoagulants. EINSTEIN-Jr phase 2 used bodyweight adjusted rivaroxaban for children with venous thromboembolism [1]. It was a single arm multicenter study three age groups &#8211; children younger [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":51843,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-51831","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EINSTEIN-Jr clinical trials of Rivaroxaban in children - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EINSTEIN-Jr clinical trials of Rivaroxaban in children - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"EINSTEIN-Jr clinical trials of Rivaroxaban in children Rivaroxaban is useful for treatment of venous thromboembolism in adults and is associated with lower risk of bleeding compared to standard anticoagulants. EINSTEIN-Jr phase 2 used bodyweight adjusted rivaroxaban for children with venous thromboembolism [1]. It was a single arm multicenter study three age groups &#8211; children younger [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-25T13:07:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-25T16:25:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/11\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1207\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"EINSTEIN-Jr clinical trials of Rivaroxaban in children\",\"datePublished\":\"2021-11-25T13:07:23+00:00\",\"dateModified\":\"2021-11-25T16:25:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/\"},\"wordCount\":539,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/\",\"name\":\"EINSTEIN-Jr clinical trials of Rivaroxaban in children - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg\",\"datePublished\":\"2021-11-25T13:07:23+00:00\",\"dateModified\":\"2021-11-25T16:25:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg\",\"width\":1207,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EINSTEIN-Jr clinical trials of Rivaroxaban in children\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EINSTEIN-Jr clinical trials of Rivaroxaban in children - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/","og_locale":"en_US","og_type":"article","og_title":"EINSTEIN-Jr clinical trials of Rivaroxaban in children - All About Cardiovascular System and Disorders","og_description":"EINSTEIN-Jr clinical trials of Rivaroxaban in children Rivaroxaban is useful for treatment of venous thromboembolism in adults and is associated with lower risk of bleeding compared to standard anticoagulants. EINSTEIN-Jr phase 2 used bodyweight adjusted rivaroxaban for children with venous thromboembolism [1]. It was a single arm multicenter study three age groups &#8211; children younger [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2021-11-25T13:07:23+00:00","article_modified_time":"2021-11-25T16:25:49+00:00","og_image":[{"width":1207,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/11\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"EINSTEIN-Jr clinical trials of Rivaroxaban in children","datePublished":"2021-11-25T13:07:23+00:00","dateModified":"2021-11-25T16:25:49+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/"},"wordCount":539,"commentCount":0,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/11\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/","url":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/","name":"EINSTEIN-Jr clinical trials of Rivaroxaban in children - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/11\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg","datePublished":"2021-11-25T13:07:23+00:00","dateModified":"2021-11-25T16:25:49+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/11\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/11\/EINSTEIN-Jr-clinical-trials-of-Rivaroxaban-in-children.jpg","width":1207,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/einstein-jr-clinical-trials-of-rivaroxaban-in-children\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"EINSTEIN-Jr clinical trials of Rivaroxaban in children"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/51831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=51831"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/51831\/revisions"}],"predecessor-version":[{"id":51845,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/51831\/revisions\/51845"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/51843"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=51831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=51831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=51831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}